bpc-157 immunogenicity risks fda Peptide Therapy for Inflammation: A New Solution BPC 157 Banned: Key Facts
Description
31 subjects spanning all Fitzpatrick skin types (IVI) completed the evaluation with no adverse reactions reported or observed
No lethal dose identified at doses up to 20 mg/kg in animal studies No organ toxicity observed across multiple organ systems Negative mutagenicity testing across standard assays No teratogenic effects in pregnancy studies Limited long-term human data beyond 6 weeks Theoretical Considerations The primary theoretical concern relates to BPC-157s angiogenic properties
We all know it
[16] [18] There is insufficient evidence to determine the risk of adverse outcomes in human pregnancies, and thus, use during pregnancy should be guided by clinical judgment and individual risk assessment
